Alteration in the laboratory profile of a lupus anticoagulant in a patient with non-Hodqkin's lymphoma

Clinical and Laboratory Haematology

Volumn 26, Issue 6, 2004, Pages 429-434

  Moore, Gary W ^a   Kamat, A V ^a   Gurney, D A ^a   O'Connor, O ^a   Rangarajan, S ^a   Carr, R ^a   Savidge, G F ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Antiphospholipid antibodies; Heterogeneity; Lupus anticoagulant; Lupus anticoagulant co factor effect; Platelet neutralisation procedure; Prothrombin time; Thromboplastin

Indexed keywords

CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY;

AGED; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BLOOD CLOTTING TIME; CASE REPORT; CELL HETEROGENEITY; DIAGNOSTIC TEST; FEMALE; HUMAN; KAOLIN CLOTTING TIME; LABORATORY DIAGNOSIS; NONHODGKIN LYMPHOMA; PARTIAL THROMBOPLASTIN TIME; PLATELET NEUTRALIZATION PROCEDURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTHROMBIN TIME; RABBIT; RUSSELL VIPER VENOM TIME; TAIPAN SNAKE VENOM TIME; THROMBOCYTE COUNT;

AGED; FEMALE; HUMANS; LUPUS COAGULATION INHIBITOR; LYMPHOMA, NON-HODGKIN; TIME FACTORS;

EID: 10844241475     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2257.2004.00644.x     Document Type: Article

References (23)

1. Arnout J. (2001) Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thrombosis and Haemostasis 86, 83-91.
2. Brandt J.T., Triplett D.A., Alving B. & Scharrer I. (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thrombosis and Haemostasis 74, 1185-1190.
3. Davis T.A. Maloney D.G., Czerwinski D.K., Lilies T.M. & Levy R. (1998) Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92, 1184-1190.
4. Exner T., Rickard K.A. & Kronenberg H. (1978) A sensitive test demonstrating lupus anticoagulant and its behavioural patterns. British Journal of Haematology, 40, 143-151.
5. Gardiner C., Mackie I.J., Malia R.G., Jones D.W., Winter M., Leeming D. & Taberner D.A. (2000) The importance of locally derived reference ranges and standardised calculation of dilute Russell's viper venom time results in screening for lupus anticoagulant. British Journal of Haematology, 111, 1230-1235.
6. Greaves M., Cohen H., Machin S.J. & Mackie I. (2000) Guidelines on the investigation and management of the antiphospholipid syndrome. British Journal of Haematology. 109, 704-715.
7. Guermazi S., Gorgi Y., Ayed K. & Dellagi K. (1997) Interference of factor VIII excess on the detection of lupus anticoagulants by the activated partial thromboplastin time. Pathologie-biologie, 45, 28-33. .
8. Jennings I., Kitchen S., Woods T.A.L. Preston F.E. & Greaves M. (1997) Potentially clinically important inaccuracies in testing for the lupus anticoagulant: an analysis of results from three surveys of the UK national external quality control scheme (NEQAS) for blood coagulation. Thrombosis and Haemostasis, 77, 934-937.
9. Lawrie A.S.. Kitchen S., Purdy G., Mackie I.J., Preston F.E. & Machin S.J. (1998) Assessment of actin FS and actin FSL sensitivity to specific clotting factor deficiencies. Clinical and Laboratory Haematology, 20, 179-186.
10. Lawrie A.S., Mackie I.J., Purdy G. & Machin S.J. (1999) The sensitivity and specificity of commercial reagents for the detection of lupus anticoagulant show marked differences in performance between photo-optical and mechanical coagulometers. Thrombosis and Haemostasis, 81, 758-762.
11. Levy R., Levy S., Cleary M., Carroll W., Kon S., Bird J. & Sklar J. (1987) Somatic mutation in human B-cell tumours. Immunological Reviews, 96, 43-58,
12. Machin S.J., Giddings J.C., Greaves M., Hutton R.A., Mackie I.J., Malia R.G. & Taberner D.A. (1991) Guidelines on testing for the lupus anticoagulant. Journal of Clinical Pathology, 44, 885-889.
13. Moore G.W., Savidge G.F. & Smith M.P. (2000) Improved detection of lupus anticoagulants by the dilute Russell's Viper venom time. Blood Coagulation and Fibrinolysis, 11, 767-774.
14. Moore G.W., Smith M.P., Patel Y. & Savidge G.F. (2002) The activated seven lupus anticoagulant (ASLA) assay: a new test for lupus anticoagulants (LAs). Evidence that some LAs are detectable only in extrinsic pathway based assays. Blood Coagulation and Fibrinolysis, 13, 261-269.
15. Moore G.W., Smith M.P. & Savidge G.F. (2003) The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinised patients with lupus anticoagulants. Blood Coagulation and Fibrinolysis, 14, 307-312.
16. Reber G., Arvieux J., Comby E., Degenne D., de Moerloose P., Sanmarco M. & Potron G. (1995) Multicentre evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thrombosis and Haemostasis, 73, 444-452.
17. Rooney A.M., McNally T., Mackie I.J. & Machin S.J. (1994) The Taipan snake venom time: a new test for lupus anticoagulant. Journal of Clinical Pathology, 47, 497-501.
18. Sanderson B.J., Johnson K.J. & Henner W.D. (2001) Induction of mutant lymphocytes in cyclophosphamide and chlorambucil treated patients. Mutagenesis, 16, 197-202.
19. II phases necessary? British Journal of Haematology 86, 583-589.
20. Ten Boekel E. & Bartels P. (2002) Abnormally short activated partial thromboplastin times are related to elevated plasma levels of TAT, F1 + 2, D-dimec and FVIII:C. Pathophysiology of Haemostasis and Thrombosis, 12, 137-142.
21. Timuragaoglu A., Duman A., Ongut G., Saka O. & Karadogan I. (2000) The significance of autoantibodies in non-Hodgkin's lymphoma. Leukaemia and Lymphoma, 40, 119-122.
22. Triplett D.A. (1994) New diagnostic strategies for lupus anti-coagulants and antiphospholipid antibodies. Haemostasis, 24, 155-164.
23. Triplett D.A. (1996) Frequent difficulties encountered in the laboratory diagnosis of antiphospholipid-protein antibodies. Annales de Medecine Interne, 147 (Suppl. 1), 5-9.